Group One Trading’s Aurinia Pharmaceuticals AUPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.78M | Buy |
120,400
+2,400
| +2% | +$35.1K | ﹤0.01% | 2184 |
|
|
2025
Q4 | $1.88M | Sell |
118,000
-68,300
| -37% | -$968K | ﹤0.01% | 2328 |
|
|
2025
Q3 | $2.06M | Buy |
186,300
+95,300
| +105% | +$1.04M | ﹤0.01% | 2295 |
|
|
2025
Q2 | $771K | Sell |
91,000
-17,400
| -16% | -$139K | ﹤0.01% | 3003 |
|
|
2025
Q1 | $872K | Sell |
108,400
-74,900
| -41% | -$607K | ﹤0.01% | 2579 |
|
|
2024
Q4 | $1.65M | Sell |
183,300
-1,903,600
| -91% | -$15.5M | ﹤0.01% | 2095 |
|
|
2024
Q3 | $15.3M | Buy |
2,086,900
+1,844,900
| +762% | +$11.4M | 0.04% | 393 |
|
|
2024
Q2 | $1.38M | Sell |
242,000
-875,500
| -78% | -$4.61M | 0.01% | 1740 |
|
|
2024
Q1 | $5.6M | Buy |
1,117,500
+274,400
| +33% | +$1.86M | 0.02% | 767 |
|
|
2023
Q4 | $7.58M | Buy |
843,100
+359,800
| +74% | +$2.96M | 0.02% | 861 |
|
|
2023
Q3 | $3.76M | Buy |
483,300
+84,000
| +21% | +$821K | 0.01% | 1128 |
|
|
2023
Q2 | $3.87M | Buy |
399,300
+179,100
| +81% | +$1.86M | 0.01% | 1162 |
|
|
2023
Q1 | $2.41M | Buy |
220,200
+117,100
| +114% | +$1.03M | 0.01% | 1377 |
|
|
2022
Q4 | $445K | Sell |
103,100
-140,600
| -58% | -$816K | ﹤0.01% | 3151 |
|
|
2022
Q3 | $1.83M | Buy |
243,700
+63,500
| +35% | +$550K | ﹤0.01% | 1997 |
|
|
2022
Q2 | $1.81M | Buy |
180,200
+13,500
| +8% | +$151K | ﹤0.01% | 2153 |
|
|
2022
Q1 | $2.06M | Sell |
166,700
-398,500
| -71% | -$6.16M | ﹤0.01% | 2367 |
|
|
2021
Q4 | $12.9M | Buy |
565,200
+15,300
| +3% | +$363K | 0.01% | 917 |
|
|
2021
Q3 | $12.2M | Buy |
549,900
+310,700
| +130% | +$4.93M | 0.01% | 918 |
|
|
2021
Q2 | $3.1M | Buy |
239,200
+117,900
| +97% | +$1.5M | ﹤0.01% | 2190 |
|
|
2021
Q1 | $1.57M | Buy |
121,300
+31,200
| +35% | +$453K | ﹤0.01% | 2726 |
|
|
2020
Q4 | $1.25M | Sell |
90,100
-25,400
| -22% | -$370K | ﹤0.01% | 2457 |
|
|
2020
Q3 | $1.7M | Sell |
115,500
-25,800
| -18% | -$374K | 0.01% | 1746 |
|
|
2020
Q2 | $2.3M | Sell |
141,300
-108,900
| -44% | -$1.74M | 0.01% | 1372 |
|
|
2020
Q1 | $3.63M | Sell |
250,200
-184,200
| -42% | -$3.25M | 0.03% | 697 |
|
|
2019
Q4 | $8.8M | Buy |
434,400
+300,700
| +225% | +$2.77M | 0.06% | 403 |
|
|
2019
Q3 | $714K | Buy |
133,700
+109,900
| +462% | +$665K | 0.01% | 2037 |
|
|
2019
Q2 | $157K | Buy |
23,800
+11,500
| +93% | +$73.3K | ﹤0.01% | 3029 |
|
|
2019
Q1 | $80K | Sell |
12,300
-31,200
| -72% | -$207K | ﹤0.01% | 3318 |
|
|
2018
Q4 | $297K | Sell |
43,500
-83,900
| -66% | -$484K | ﹤0.01% | 2374 |
|
|
2018
Q3 | $846K | Buy |
127,400
+1,900
| +2% | +$10.7K | 0.01% | 1835 |
|
|
2018
Q2 | $707K | Sell |
125,500
-90,100
| -42% | -$503K | 0.01% | 2014 |
|
|
2018
Q1 | $1.12M | Sell |
215,600
-108,900
| -34% | -$583K | 0.01% | 1437 |
|
|
2017
Q4 | $1.47M | Buy |
324,500
+75,300
| +30% | +$418K | 0.01% | 1401 |
|
|
2017
Q3 | $1.56M | Buy |
249,200
+8,500
| +4% | +$53.6K | 0.01% | 1227 |
|
|
2017
Q2 | $1.48M | Sell |
240,700
-19,100
| -7% | -$129K | 0.02% | 1163 |
|
|
2017
Q1 | $1.91M | Buy |
259,800
+249,800
| +2,498% | +$1.15M | 0.02% | 895 |
|
|
2016
Q4 | $21K | Buy |
+10,000
| New | +$32.2K | ﹤0.01% | 3680 |
|
Other funds holding AUPH
TCM
NMC
Group One Trading's AUPH Position: Q1 2026 in Review
Group One Trading opened a new position in Aurinia Pharmaceuticals (AUPH) in Q1 2026: 19,219 shares worth $285K. The stake represents ﹤0.01% of the portfolio and ranks #3849 among its holdings. This is a return to the name: Group One Trading previously reported a position in AUPH as recently as Q2 2025.
Group One Trading first reported a position in AUPH in Q1 2017 and has held it in 34 quarters since. The position peaked at $6.1M in Q4 2023. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.
- Group One Trading held 19,219 shares of Aurinia Pharmaceuticals worth $285K as of Q1 2026.
- Aurinia Pharmaceuticals was a new Group One Trading position in Q1 2026.
- Aurinia Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #3849 holding.
- Group One Trading first reported a position in Aurinia Pharmaceuticals in Q1 2017 and has held it in 34 quarters since.
- Group One Trading's Aurinia Pharmaceuticals position peaked at $6.1M in Q4 2023.
- 259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.
Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.